DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to compounds of the formula

1 wherein R represents O or S; 2 R represents alkyl of C1-C10, phenyl, naphthyl, or phenyl substituted by one or two substituents, each of which is independently halo, loweralkyl of C1-C4, loweralkoxy of C1-C4, benzyloxy, nitro, or

wherein each R is independently loweralkyl of C1-C4; and R 3a 3a represents hydrogen or-CH2-R wherein R represents alkyl of C1-C11 4 alkyl of C1-C11-R, or 4 4 1)-R)0or1,R-(0(0or 4 wherein each R is independently phenyl or phenyl substituted by one or two substituents, each of which is independently halo, loweralkyl of C1-C4, loweralkoxy of C1- C4, or loweralkylthio of Cl-C4, and pharmaceutically acceptable salts thereof.

The compounds of the present invention are prepared by reacting a parent glycopeptide of the formula

3 wherein R is as defined above, with an isocyanate or isothiocyanate of the formula R1CN-R2, wherein R1 and are as defined above. This is the first step of the so-called Edman degradation, which is a two-step process for the cleavage of the N-terminal residue of a peptide or protein.

The reaction to prepare the present compounds is carried out in a polar solvent, such as water, in the presence of an organic base, such as pyridine. Generally the reaction is carried out at a temperature of about 15°C to about 35°C for one to five hours. The reaction is preferably carried out at a temperature from about 25°C to 30°C for one to two hours, in water with pyridine as the base. The reaction consumes equimolar amounts of the reactants but a slight excess of the isocyanate or isothiocyanate is preferred. The product is separated and purified if desired in conventional procedures. When it is desired, a salt can be prepared in standard procedures.

The following examples illustrate the preparation of the compounds of the present invention.

Preparation of Compound of Example 22 DISACC N- (p- (p-Chlorophenyl) benzyl) A82846B trihydrochloride (100.0 mg, 0.0526 mmol) was dissolved in 10 ml H2O-pyridine (1: 1 v/v) and treated with phenyl isothiocyanate (0.010 ml, 0.083 mmol). The resulting mixture was stirred at room temperature for 1 hour at which time HPLC analysis indicated complete consumption of the starting material. The reaction mixture was concentrated in vacuo and the crude product was purified by preparative HPLC to give 76.6 mg (76% yield) of NLEU- (phenylthiocarbamoyl)-

DISACC N- (p- (p-chlorophenyl) benzyl) A82846B. FAB-MS: calc. For C93H102Cl3N11O26S 1925.5, obtained 1928.5 (M+3).

Preparation of Compound of Example 23 A82846B triacetate (270 mg, 0.157 mmol) was dissolved in 30 ml H, O-pyridine (1: 1 v/v) and treated with phenyl isocyanate (0.030 ml, 0.277 mmol). The resulting mixture was stirred at room temperature for 1 hour at which time HPLC analysis indicated complete consumption for the starting material. The reaction mixture was concentrated in vacuo and the crude product was purified by preparative HPLC to give 62.5 mg (23% yield) of N-(phenylcarbamoyl)- <BR> <BR> <BR> <BR> <BR> A82846B. FAB-MS: Calc. For C80H93Cl2NllO27 1709.6, obtained 1712.1 (M+3).

The HPLC procedures reported in these examples were as follows: Analytical: Reactions were monitored by analytical HPLC using a Waters C18 uBondapak or Novapak C18 column (3.9x300 mm) and W detection at 280 nm. Elution was accomplished with a linear gradient of 5% CH3CN-95% buffer to 80% CH3CN-20% buffer over 30 minutes. The buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H3PO4- Preparative: Crude reaction mixtures were purified by preparative HPLC using a Waters C18 Nova-Pak column (40x300 mm) and W detection at 280 nm. Elution was accomplished with a linear gradient of 5% CH3CN-95% buffer to 80% CH3CN -20% buffer over 30 minutes. The buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H3PO4. The

desired fractions were subsequently desalted with a Waters C18 Sep-Pak (35 cc) followed by lyophilization.

Compounds were desalted as follows. A Waters Sep-Pak cartridge was pre-wet with methanol (2-3 column volumes) then conditioned with water (2-3 column volumes). The sample, dissolved in a minimum volume of water, was loaded onto the Sep-Pak column which was then washed with water (2- 3 column volumes) to remove the unwanted salts. The product was then eluted with an appropriate solvent system, typically 1: 1 CH3CN/H20, CH3CN, and/or methanol. The organic solvent component was removed in vacuo and the resulting aqueous solution lyophilized to give the final product.

Representative compounds of the present invention are listed in the following table: TABLE I Ex Analytical # Name FAB-MS M+X HPLC, min NLEU- 1728. 5 3 18.2* (PHENYLTHIOCARBAMOYL) A82846B 2 NU-(PHENYLTHIOCARBAMOYL)-1852. 3 3 21. 4* DISACC N- (p-CHLOROBENZYL) A82846B 3 NU-(PHENYLTHIOCARBAMOYL)-1911. 0 3(PHENYLTHIOCARBAMOYL)-1911. 0 3 23.6* DISACC N- (p-PHENOXYBENZYL)- A82846B NLEU-(PHENYLTHIOCARBAMOYL)- 1894. 5 3 23.2* DISACC N- (p-PHENYLBENZYL) A82846B NLEU-(1-NAPHTHYLTHIOCARBAMOYL) 1778.5 3 19.8* A82846B 6 NLEU-(1- 1902. 5 3 15.4* DISACC NAPHTHYLTHIOCARBAMOYL)-N (p-CHLOROBENZYL) A82846B 317.1*NLEU-(1-1960.6 DISACC NAPHTHYLTHIOCARBAMOYL)-N (p-PHENOXYBENZYL) A82846B NLEU- ( (p-CHLOROPHENYL)- 1763.0 4 20. 5* THIOCARBAMOYL) A82846B 221.0*NLEU-((p-METHOXYPHENYL)-1757.L3 THIOCARBAMOYL) A82846B 10 NLEU-((p-CHLOROPHENYL)- 1944. 3 3 26.9* DISACC THIOCARBAMOYL)-N- (p- PHENOXYBENZYL) A82846B 11 NLEu ( (p-METHOXYPHENYL)- 1940.3 3 2 6. 0 DISACC THIOCARBAMOYL)-N- (p- PHENOXYBENZYL) A82846B 12 NLEU- ( (p-CHLOROPHENYL)-1887.5 4 24.8* DISACC THIOCARBAMOYL)-N- (p- CHLOROBENZYL) A82846B TABLE I (Cont.) Ex Analytical # Name FAB-MS M+X HPLC, min 13 NLEU-((p-METHOXYPHENYL)- 1882.5 3 25.2* DISACC THIOCARBAMOYL)-N-(p- CHLOROBENZYL) A82846B 14 NLE°- (p-NITROPHENYL)-1774.0 3 19.1* THIOCARBAMOYL) A82846B 15 NLEU-((p-(DIMETHYLAMINO)- 1771.4 3 17.6* PHENYL) THIOCARBAMOYL) A82846B 16 NLE - (p- (BENZYLOXY) PHENYL)- 1834.4 3 23. 3* THIOCARBAMOYL) A82846B 17 NLEU-((p-n-BUTYLPHENYL) 1784.((p-n-BUTYLPHENYL) 1784. 4 3 17.0* THIOCARBAMOYL) A82846B 18 N ( (p-n-BUTYLPHENYL)- 1966.5 3 21.4** DISACC THIOCARBAMOYL)-N-(p- PHENOXYBENZYL) A82846B 19 NLEU- ((p-(DIMETHYLAMINO) 1953.3 3 17.1** DISACC PHENYL) THIOCARBAMOYL)-N- (p-PHENOXYBENZYL) A82846B 20 NLEU-((p-(BENZYLOXY)PHENYL)- 2016. 3 3 21.1** DISACC THIOCARBAMOYL)-N-(p- PHENOXYBENZYL) A82846B 21 NLEU-(PHENYLTHIOCARBAMOYL)- 1874. 6 3 19.0** DISACC N-(p-n-BUTYLBENZYL)- A82846B 22 NLEU-(PHENYLTHIOCARBAMOYL)- 1928. 5 3 20.3** DISACC N-(p-(p-CHLOROPHENYL)- BENZYL) A82846B 23 NLEU-(PHENYLCARBAMOYL)A82846B 1712.1 3 13.8** 24 N-(PHENYLCARBAMOYL)-N-1894. 2(PHENYLCARBAMOYL)-N-1894. 2 3 18.9** (p-PHENOXYBENZYL) A82846B NLEU-(n-DECYLTHIOCARBAMOYL)-1792.(n-DECYLTHIOCARBAMOYL)-1792 . 4 3 N. A. A82846B

*Waters C18 Nova-Pak column **Waters C18 µBondapak

The compounds of the present invention are useful for the treatment of bacterial infections. Therefore, in another embodiment, the present invention is directed to a method for controlling a bacterial infection in a host animal, typically a warm-blooded animal, which comprises administering to the host animal an effective, antibacterial amount of a compound of the present invention. In this embodiment, the compounds can be used to control and treat infections due to various bacteria, but especially gram- positive bacteria. In a preferred embodiment, the compounds are used to control and treat infections due to bacteria resistant to existing antibacterials. For example, certain bacteria are resistant to methicillin, and yet others are resistant to vancomycin and/or teicoplanin. The present compounds provide a technique for controlling and treating infections due to such resistant bacterial species.

In carrying out this embodiment of the invention, the compounds of the present invention can be administered by any of the conventional techniques, including the oral route and parenteral routes such as intravenous and intramuscular.

The amount of compound to be employed is not critical and will vary depending on the particular compound employed, the route of administration, the severity of the infection, the interval between dosings, and other factors known to those skilled in the art. In general, a dose of from about 0.5 to about 100 mg/kg will be effective; and in many situations, lesser doses of from about 0.5 to about 50 mg/kg will be effective. A compound of the present invention can be administered in a single dose, but in the known manner of antibacterial therapy, a compound of the present invention is typically administered repeatedly over a period of time, such as a matter of days or weeks, to ensure control of the bacterial infection.

Also in accordance with known antibacterial therapy, a compound of the present invention is typically formulated for convenient delivery of the requisite dose. Therefore, in another embodiment, the present invention is directed to a pharmaceutical formulation comprising a compound of the present invention, in combination with a pharmaceutically- acceptable carrier. Such carriers are well known for both oral and parenteral routes of delivery. In general, a formulation will comprise a compound of the present invention in a concentration of from about 0.1 to about 90% by weight, and often from about 1.0 to about 3%.

The antibacterial efficacy of the present compounds is illustrated by Table II. The minimal inhibitory concentrations (MICs) were determined using a standard broth micro-dilution assay. TABLE II. Antibacterial Activity, Minimal Inhibitory Concentration (MIC) Against Various Organisms* Ex RESISTANT SENSITIVE SA SA SA SH SH SE SPY SPN 446 489 447 105 415 270 C203 P1 1 >128 16 8 4 8 64 >64 8 2 2 2 128 3. 4 2 2 2 8 16 4 0.125 0.25 1.7421221#.06316 4 14 4 2 0. 125 1 2 1 0.5 #0. 06 0.125 5 >128 9. 5 8 >64 8 64 >64 32 0.5 1 52@1644864#0.06#0.066128 7 19 3 4 2 1 4 2 0.5 0.25 #0. 06 8 >128 8 2 2 4 16 64 8 9 >128 21 8 4 8 32 32 16 10 9. 5 1. 7 4 2 2 1 2 2 11 38 2. 6 4 2 2 1 2 2 3.5411241#0.06#0.0612128 13 >128 3. 5 4 2 2 4 8 2 <0. 06 <0.06 14>1283. 5224163240. 06 0.25 15 >128 24 8 4 16 >64 >64 16 0.25 0.25 16 >128 7 1 0.5 1 8 64 4 #0. 06 0.125 6.1211432217>128 #0.06 18 4. 7 1. 7 2 2 2 2 2 2 0.25 2 19 19 2. 6 2 2 2 2 4 2 0.25 2 209. 55. 64222210.06 4 21 32 2.6 22 6. 7 2. 6 2 1 1 1 2 0.5 <. 06 <. 06 23 >128 5. 3 4 1 4 0. 5 64 4 24 16 0. 87 2 1 1 0. 25 1 1 * ABBREVIATIONS ORGANISM RESISTANT Enterococcus faecium and faecalis (geometric mean of 4-6 isolates) SENSITIVE Enterococcus faecium and faecalis (geometric mean of 4-6 isolates) SA446 Staphylococcus aureus 446 SA489 Staphylococcus aureus 489 SA447 Staphylococcus aureus 447 SH 105 Staphylococcus haemolyticus 105 SH 415 Staphylococcus haemolyticus 415 SE 270 Staphylococcus epidermidis 270 SPY C203 Streptococcus pyogenes C203 SPN P1 Streptococcus pneumoniae P1

LEU The N-thiocarbamoyl compounds of the present invention can also be employed as starting materials to other antibacterial compounds. This use is illustrated by the following reaction sequence: present p, hexapeptides p. NI-alkylated compounds hexapeptides Thus, a present compound is treated with an organic acid, preferably trifluoroacetic acid, in a non-polar solvent, and at a temperature of from about 0°C to 35°C. This treatment, the second step of an Edman degradation, results in the loss of the leucine group including the thiocarbamoyl substituent. The resulting"hexapeptides"exhibit antibacterial activity and can be employed as described above for the present compounds.

The hexapeptide can thereafter be reductively alkylated to introduce an alkyl group on the amine freed up by the 1 preceding process, the"N"amine. Alkylation is achieved by reacting the hexapeptide with an aldehyde to form a Schiff's base, which is then reduced to obtain the N- alkylhexapeptide. Both reactions are carried out in a polar

solvent, such as DMF, and at temperatures of 0-100°C, preferably 60-70°C. The preferred reducing agent is sodium cyanoborohydride. In one embodiment, the reducing agent is added at the same time as the hexapeptide and aldehyde. The resulting N1-alkylated hexapeptides are useful as antibacterials and can be employed as described above for compounds of the present invention.